A triple-combination therapy for BRAF-V600E mutated colorectal cancer
The researchers from multicenter research institutions published a study in the New England Journal of Research, revealing that a combination of Encorafenib, Binimetinib, and Cetuximab could prolong the overall survival among patients with BRAF mutated colorectal...